Furthermore, the combination of Fyn inhibition within glioma cells and cancer immunotherapy, such as immune checkpoint blockade (PDL1 and PD1 inhibitors), IFNγ therapy, and Ad-hCMV-TK plus Ad-hCMV-Flt3L immune-stimulatory gene therapy (8, 12, 278), are promising avenues to improve the efficacy of anti-glioma immunotherapies and explore novel personalized treatment for glioma patients. The gene discussed is FLT3LG; the disease is central nervous system cancer.